Annual report pursuant to Section 13 and 15(d)

Stockholders' Equity (Tables)

v3.21.1
Stockholders' Equity (Tables)
12 Months Ended
Dec. 31, 2020
Stockholders' Equity  
Stock Based Compensation Plans of Partner Companies

Certain partner companies have their own equity compensation plan under which shares are granted to eligible employees, directors and consultants in the form of restricted stock, stock options, and other types of grants of stock of the respective partner company’s common stock. The table below provides a summary of those plans as of December 31, 2020:

Partner

Shares

Shares available at

Company

    

Stock Plan

    

Authorized

    

December 31, 2020

Aevitas

Aevitas Therapeutics, Inc. 2018 Long Term Incentive Plan

2,000,000

1,602,000

Avenue

 

Avenue Therapeutics, Inc. 2015 Stock Plan

 

2,000,000

 

229,436

Baergic

 

FBIO Acquisition Corp. III 2017 Incentive Plan

 

2,000,000

 

1,150,000

Cellvation

 

Cellvation Inc. 2016 Incentive Plan

 

2,000,000

 

300,000

Checkpoint

 

Checkpoint Therapeutics, Inc. Amended and Restated 2015 Stock Plan

 

9,000,000

 

4,288,465

Cyprium

 

Cyprium Therapeutics, Inc. 2017 Stock Plan

 

2,000,000

 

575,000

Helocyte

 

DiaVax Biosciences, Inc. 2015 Incentive Plan

 

2,000,000

 

341,667

Journey

 

Journey Medical Corporation 2015 Stock Plan

 

3,642,857

 

34,000

Mustang

 

Mustang Bio, Inc. 2016 Incentive Plan

 

5,000,000

 

1,180,085

Oncogenuity, Inc.

FBIO Acquisition Corp. VII 2017 Incentive Plan

2,000,000

1,600,000

Tamid

 

FBIO Acquisition Corp. V 2017 Incentive Plan

 

2,000,000

 

1,600,000

Schedule of Stock-Based Compensation Expense

The following table summarizes the stock-based compensation expense from stock option, employee stock purchase programs and restricted Common Stock awards and warrants for the years ended December 31, 2020 and 2019

Year Ended December 31, 

($ in thousands)

    

2020

    

2019

Employee awards

$

4,991

$

3,666

Executive awards of Fortress Companies' stock

 

1,504

 

1,428

Non-employee awards

 

159

 

121

Warrants

130

97

Partner Companies:

Avenue

 

710

 

1,839

Checkpoint

 

2,780

 

3,121

Mustang

 

2,987

 

2,664

Other

 

190

 

252

Total stock-based compensation expense

$

13,451

$

13,188

Schedule of Stock Option Activities

The following table summarizes Fortress stock option activities excluding activities related to partner companies:

Weighted average

Total

remaining

Weighted average

weighted average

contractual life

    

Shares

    

exercise price

    

intrinsic value

    

(years)

Options vested and expected to vest at December 31, 2018

1,285,501

$

3.75

$

2.93

Granted

125,000

1.18

173,750

Options vested and expected to vest at December 31, 2019

 

1,410,501

$

4.30

$

684,752

 

2.33

Exercised

 

(100,000)

1.18

 

 

Forfeited

(257,011)

2.57

Options vested and expected to vest at December 31, 2020

 

1,053,490

$

5.02

$

647,482

 

2.63

Schedule of Restricted Stock Awards and Restricted Stock Units

The following table summarizes Fortress restricted stock awards and restricted stock units activities, excluding activities related to Fortress subsidiaries:

    

    

Weighted

average grant

Number of shares

price

Unvested balance at December 31, 2018

 

12,645,982

$

2.72

Restricted stock granted

 

1,546,408

 

0.88

Restricted stock vested

 

(220,000)

 

3.16

Restricted stock units granted

290,000

1.49

Restricted stock units forfeited

 

(135,416)

 

3.91

Restricted stock units vested

 

(358,960)

 

3.61

Unvested balance at December 31, 2019

13,768,014

$

2.46

Restricted stock granted

1,873,072

2.57

Restricted stock vested

(230,000)

2.78

Restricted stock units granted

630,126

3.82

Restricted stock units forfeited

(148,750)

3.30

Restricted stock units vested

(384,958)

3.49

Unvested balance at December 31, 2020

15,507,504

$

2.49

Schedule of Warrant activities

The following table summarizes Fortress warrant activities, excluding activities related to partner companies:

Total weighted

Weighted average

average

remaining

Number of

Weighted average

 intrinsic

contractual life

    

shares

    

exercise price

    

value

    

(years)

Outstanding as of December 31, 2018

 

2,754,189

$

3.28

$

3.49

Granted

60,000

1.92

39,000

Forfeited

(73,009)

 

5.65

 

Outstanding as of December 31, 2019

 

2,741,180

$

3.19

$

111,000

 

2.73

Granted

 

1,849,450

 

3.14

 

101,000

 

Forfeited

 

(9)

 

3.00

 

2

 

Outstanding as of December 31, 2020

 

4,590,621

$

3.17

$

607,848

 

4.85

Exercisable as of December 31, 2020

 

4,430,621

$

3.21

$

452,848

 

4.80